Review Article
Integrin Inhibitors as a Therapeutic Agent for Ovarian Cancer

Kenjiro Sawada,1 Chifumi Ohyagi-Hara,1 Tadashi Kimura,1 and Ken-ichirou Morishige2

1 Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
2 Department of Obstetrics and Gynecology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu 501-1194, Japan

Correspondence should be addressed to Ken-ichirou Morishige, mken@gifu-u.ac.jp

Received 14 September 2011; Revised 11 November 2011; Accepted 17 November 2011

Copyright © 2012 Kenjiro Sawada et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Ovarian cancer is a deadly disease, with a cure rate of only 30%. Despite aggressive treatments, relapse remains almost inevitable in patients with advanced-stage disease. In recent years, great progress has been made towards targeting integrins in cancer treatment, and clinical studies with various integrin inhibitors have demonstrated their effectiveness in blocking cancer progression. Given that the initial critical step of ovarian cancer metastasis is the attachment of cancer cells onto the peritoneum or omentum, in addition to the proven positive clinical results of anti-angiogenic therapy, targeting integrins is likely to be one of the most feasible approaches. This paper summarizes the current understanding of the integrin biology in ovarian cancer metastasis and the various therapeutic approaches attempted with integrin inhibitors. Although no integrin inhibitors have shown favorable results so far, integrin-targeted therapies continue to be a promising approach to be explored for further clinical investigation.

1. Introduction

Ovarian cancer is a highly metastatic disease characterized by widespread peritoneal dissemination and ascites and is the leading cause of death from gynecologic malignancies. It is often diagnosed at a late stage after tumor cells are disseminated within the peritoneal cavity. Despite aggressive treatments which consist of surgical cytoreduction and chemotherapy, more than two-thirds of all patients succumb to the disease within 5 years [1]. The initial step of ovarian cancer metastasis is that cancer cells, detached from the ovarian surface epithelium, attach to the layer of mesothelial cells that line the inner surface of the peritoneum. Several integrins have been identified as important mediators of ovarian carcinoma metastasis to the mesothelium, suggesting that integrin inhibitors could be a new therapeutic strategy to prevent cancer cells from attaching onto the peritoneal cavity. During the last 10 years, novel insights into the mechanisms that regulate cell survival as well as cell migration and invasion have led to the development of novel integrin inhibitors for cancer treatments [2]. In this short review, we describe the critical roles of integrins during the metastatic process of ovarian carcinoma and discuss the potential of integrin inhibitors as a new therapeutic agent for the treatment of ovarian cancer.

2. Biology of Integrin

The role of integrins in cell migration and invasion is one of their most studied functions in tumor biology [3, 4]. Integrins are cellular surface glycoprotein receptors consisting of a heterodimer of α- and β-subunits that are mutually non-covalently associated. In mammals, integrins have extensive distributions throughout the whole body, and there are 18 α- and 8 β-subunits assembling 24 functionally different heterodimers [5, 6]. Each individual integrin subunit has a large extracellular domain, a single membrane-spanning domain and a short noncatalytic cytoplasmic tail. The assembled integrin heterodimer can bind to a unique set of ligands. Natural integrin ligands include the components of the extracellular matrix (ECM) such as collagen, laminin, fibronectin, and vitronectin. Many integrins bind their ligands by recognizing the short amino acid sequences on exposed loops, such as Arg-Gly-Asp (RGD) (integrin α5β1) or Arg-Glu-Asp-Val (REDV) (integrin α4β1). On ligation to the ECM, integrins recruit complex signaling events, alone or in combination with growth factor receptors. Integrin signaling regulates diverse functions in tumor cells, including migration, invasion, proliferation, and survival through the activation of various pathways, such as integrin-linked kinase (ILK), mitogen-activated protein kinase (MAPK),
protein kinase B (PKB/Akt), or nuclear factor kappa B (NF-κB) [7]. In recent years, great progress has been made towards targeting integrins in cancer treatment. Preclinical as well as clinical studies with various integrin antagonists have demonstrated their effectiveness in blocking tumor progression [3]. Almost all such Phase 1 clinical trials showed that the integrin inhibitors are nontoxic and well tolerated by patients, suggesting that they can be used concurrently with the conventional cytotoxic chemotherapy or radiotherapy. Some reports showed that radiotherapy results in up-regulation of integrin expression in several types of cancer, leading to cellular resistance to radiotherapy-induced cancer cell death [8, 9]. Nam et al. demonstrated in their preclinical works that targeting β1-integrin enhances the efficacy of radiation therapy in several cancers including breast cancer [9]. Integrins are also involved in innate multidrug resistance, allowing tumor cells to survive chemotherapy (cell-adhesion-mediated drug resistance: CAM-DR) [8]. It has been proposed that CAM-DR is caused by the activation of β1-integrin-stimulated tyrosine kinase that suppresses apoptosis from chemotherapy [10, 11]. Integrin-targeted therapies in addition to conventional cytotoxic treatments, thus, have great potential to enhance the efficacy of overall treatments with minimal side effects.

3. Ovarian Cancer Metastasis and Current Treatment Options

In 2010, the American Cancer Society estimated that there were 21,880 cases of epithelial ovarian carcinoma and 13,850 disease-related deaths, identifying that ovarian cancer has the highest mortality rate of all gynecologic tumors. Sixty-three percent of all patients with ovarian carcinoma will succumb to their disease, making it the fifth leading cause of cancer death among USA women [12]. The high mortality of this tumor is largely explained by the fact that the majority of patients present at an advanced stage, with widespread metastatic disease within the peritoneal cavity. Only 20% of ovarian cancers are diagnosed while they are still limited to the ovaries, and patients at this early stage have an 85–90 percent 5-year survival [13].

In spite of several efforts made for early screening of ovarian cancer, no effective screening methods have been established to reduce ovarian cancer incidence and mortality [14]. Current treatment strategies for advanced ovarian carcinoma consist of aggressive “cytoreductive” or “tumor-debulking” surgery, followed by a combination of platinum- and taxane-based chemotherapy. The surgical treatment goal is “optimal” surgical cytoreduction, which is generally defined as residual disease of 1 cm or less. No gross residual tumors should be left throughout the abdominal cavity, because several studies have convincingly shown that cytoreduction results in improved patient survival [15, 16]. This effect of cytoreduction is indicative of a dramatic difference in the biological behavior of ovarian cancer as compared with other malignancies, because in most other cancers the removal of metastatic tumors does not necessarily lead to improved survival [13]. One of the main reasons for this difference is that, unlike other malignancies, ovarian cancer directly disseminates within the abdominal cavity and rarely disseminates through the vasculature unlike other malignancies, although metastasis in pelvic and/or para-aortic lymph nodes can be found occasionally [17]. Once the cancer cells have detached as single cells or clusters from the primary ovarian tumor, it is thought that they metastasize through a passive mechanism, carried by the physiological movement of peritoneal fluid to the peritoneum and omentum. However, in spite of the execution of primary aggressive cytoreductive surgery as well as meticulously-designed chemotherapy regimens, the overall cure rate of ovarian cancer patients remains approximately 30% [13]. Even though no apparent tumors remain throughout the peritoneal cavity after the initial surgery, invisible cancer cells are left and endure through the postoperative chemotherapy. Small numbers of drug-resistant cells can persist for many months and remain dormant in the peritoneal cavity, only to grow progressively, leading to death of the patient despite aggressive treatment of the recurrent disease. There is, thus, a critical need for novel targeted therapies to overcome this situation. In particular, efficacious consolidation or maintenance therapy after the cytoreduction surgery needs to be explored.

Novel molecularly directed therapies which aim to target tumor cells and the tumor microenvironment in ovarian tumorigenesis are rapidly emerging. Antiangiogenic agents have led the field so far. Preclinical and clinical studies have demonstrated the efficacy of antiangiogenic approaches against ovarian cancer both alone and in combination with cytotoxic chemotherapy [18]. Bevacizumab, a humanized monoclonal antibody directed against VEGF, has been tested in several epithelial malignancies, including ovarian cancer. Several prospective Phase II trials have shown that bevacizumab in combination with chemotherapy (carboplatin-paclitaxel, cyclophosphamide, or topotecan) is efficacious in advanced ovarian cancer [19], and Phase III evaluation is currently ongoing. Although these results are promising and it appears to be clear that bevacizumab is efficacious in a subset of ovarian cancer patients, resistance to bevacizumab is a major obstacle even for patients in whom bevacizumab was initially efficacious [18]. One potential alternative treatment option is targeting integrins, which regulate diverse functions in tumor cells including adhesion, migration, invasion, proliferation, and survival. In addition to tumor cells, integrins are also found on tumor-associated host cells, such as the vascular endothelium, fibroblasts, or bone marrow-derived cells. Targeting integrin signaling has the potential to inhibit the contribution of these cell types to cancer progression [3]. Several integrin-targeted therapeutic agents are emerging and currently in clinical trials for cancer therapy including ovarian carcinoma.

4. Integrin Biology in Ovarian Cancer

Most ovarian cancer cells are derived from the epithelial cells that cover the surface of the ovary [1]. Before the ovarian carcinoma cells detach from the basement membrane, they often undergo an epithelial-mesenchymal transition (EMT),
which loosens the intercellular adhesions between the cancer cells. EMT often starts from the loss of E-cadherin, one of the molecules crucial for the adhesion between neighboring epithelial cells. During the process of EMT, cancer cells acquire a more invasive phenotype and proliferate and spread throughout the abdominal cavity, carried by the physiological movement of massive ascites. Indeed, the knockdown of E-cadherin was reported to induce the up-regulation of the fibronectin receptor, α5β1-integrin, which promotes the adhesion of ovarian cancer cells to secondary metastasis sites, such as omentum and peritoneum [17, 20]. According to an immunohistochemical analysis using clinical samples conducted at the University of Chicago (Chicago, IL), about 40% (42 of 107) advanced (Stages II–IV) ovarian cancer patients showed α5β1-integrin positive staining. Among these positive cases, 10 cases (9%) were considered to show overexpression and the median survival of the patients with α5β1-integrin overexpression was significantly worse (26 months) than that of those with low or negative integrin expression (35 months) [20]. Once the cancer cells have detached from the primary tumor, they float in the ascites as single cells or as multicellular spheroids. Casey et al. reported that the β1-integrin stimulating antibody or exogenous treatment with fibronectin promoted the spheroid formation of ovarian cancer cells, while blocking antibodies against α5- or β1-integrin inhibited the formation, indicating that interactions between α5β1-integrin and fibronectin mediate the formation of ovarian carcinoma spheroids and their adhesion to ECMs at the secondary tumor growth sites [21]. The initial key step of ovarian cancer metastasis is the attachment of ovarian cancer cells onto the layer of mesothelial cells which cover the peritoneal cavity. Integrins have also been identified as important mediators between ovarian carcinoma and the mesothelium. Strobel and Cannistra reported that blocking antibodies against α5- and β1-Integrin as well as RGD peptide inhibited the binding of ovarian cancer cells to mesothelial cells, suggesting that α5β1-integrin was the major receptor responsible for fibronectin-mediated ovarian cancer binding to the mesothelium [22]. These accumulating results strongly suggest that inhibition of α5β1-integrin is a potential new therapeutic target, at least for a subset of ovarian cancer patients [21]. Not only fibronectin but also collagen and laminin are the most abundant extracellular proteins in the mesothelium covering the peritoneum and the omentum. Primary ovarian carcinoma cells adhere preferentially to type I collagen, which can be blocked with an α2β1-integrin antibody [23]. The other important adhesion molecules which interact with cancer cells and the mesothelial cells are α4β1-integrin and its adhesion receptor, cell adhesion molecule-1 (VCAM-1) [24]. α4β1-integrin expressed on ovarian carcinoma cells binds to VCAM-1, which is present on the mesothelial cells and function-blocking antibodies directed against VCAM-1 and α4β1-integrin block migration and metastasis in a xenograft model [24]. The expression of αvβ6 integrin in ovarian cancer cell lines correlates with the invasive potential of cells by inducing the secretion of proteinases such as urokinase plasmin activator (uPA) and matrix metalloproteinases (MMPs) [25]. Inconsistent results have been reported regarding the role of the vitronectin receptor, αvβ3-integrin, in ovarian cancer metastasis. Although it was initially thought to be expressed on aggressive ovarian cancer cells and to be correlated with ovarian cancer cell adhesive, migratory, and proliferative properties, recent data question this assertion and indicate that it is expressed on well-differentiated tumors and acts as a tumor suppressor in ovarian cancer [17]. Kaur et al. reported that αvβ3-integrin-expressing ovarian cancer cells showed impaired invasion, protease expression, and colony formation and that patients with tumors expressing high levels of β3-integrin had significantly better prognoses [26]. Given that Reynolds et al. recently showed that nanomolar concentrations of RGD-mimetic αvβ3-/αvβ5-integrin inhibitors enhance tumor growth and tumor angiogenesis in preclinical xenograft models [27], therapies aimed at blocking αvβ3-integrin may have detrimental effects.

5. Clinical Trials Targeting Ovarian Cancer

Preclinical studies have shown that integrin antagonists inhibit tumor growth by affecting both tumor cells and tumor-associated host cells, especially the angiogenic endothelium. Integrin antagonists currently in clinical trials include monoclonal antibodies and Arg-Gly-Asp (RGD) peptide mimetics [3, 31]. The candidate integrin inhibitors which could be applied for ovarian cancer treatment are summarized in Table 1 [20, 26, 29, 30]. Vocoliximab, a chimeric monoclonal antibody directed against α5β1-integrin, inhibits angiogenesis and impedes tumor growth. Bell-McGuinn et al. reported on their Phase II data of platinum-resistant ovarian cancer patients treated with volociximab as a monotherapy [32]. Of 14 patients who were evaluable for efficacy, only one patient had stable disease at 8 weeks, and the remaining 13 progressed on treatment, although weekly volociximab was well tolerated. Beside the antibodies, synthetic peptides that mimic the structure of natural integrin binding ligands are alternative candidates for integrin inhibitors [6]. ATN-161 is a non-RGD-based pentapeptide binding to α5β1- and αvβ3-integrins, derived from fibronectin by replacing an arginine residue of the primary sequence with cysteine moieties [6]. It has been shown to inhibit tumor growth, angiogenesis, and metastasis in multiple animal models [28, 33]. In Phase I safety trials, ATN161 was well tolerated, and several patients exhibited stable disease, including one ovarian carcinoma [34]. Since the 1990s, αvβ3-integrin has been identified as a target for antiangiogenic therapy, as it expresses in proliferating vascular endothelial cells and regulates endothelial cell migration in sprouting vessels [24]. LM609, a mouse anti-human monoclonal antibody raised against αVβ3-integrin, showed considerable antiangiogenic activity in preclinical models [35]. As a result of these studies, etaracizumab (MEDI-522), a humanized version of LM609, was developed as one of the first integrin antagonists introduced into clinical trials. However, clinical trials found it to have limited effectiveness as a metastatic cancer treatment, probably owing to the single integrin (αVβ3-) targeting [6, 36]. The human αv-integrin specific monoclonal antibody, intetumumab (CNTO-95),
which targets both αvβ3- and αvβ5-integrins, also showed antitumor and antiangiogenic effects in xenograft tumor models [37, 38]. In a Phase I clinical trial, intetumumab was nontoxic, localized to tumors, and showed signs of antitumor activity [39]. A complete response imaged by FDG-PET was observed in one patient with ovarian carcinosarcoma whose disease remained stable for 6 months while receiving intetumumab [40]. This antibody should be further evaluated in additional clinical trials. Among various available RGD mimic peptides, cilengitide (c-[RGDF(NMe)V-]) has emerged as a promising agent. It can bind to both αvβ3- and αvβ5-integrins with high affinity and inhibit their function strongly [6]. Cilengitide has shown significant promise in patients with late-stage glioblastoma by extending patient survival with minimal side effects [41, 42]. It is currently being tested in Phase II trials in patients with lung and prostate cancer, and Phase II and Phase III trials are currently underway for glioblastoma [3]. However, in moving toward ovarian cancer clinical trials with cilengitide, a serious concern needs to be addressed. As noted above, Kaur et al. suggested that increased αvβ3-integrin expression on ovarian cancer cells correlates with a favorable outcome and that inhibiting its activity could increase the severity of the disease [26]. Therefore, it is critical to further investigate and clarify the effects of anti-αvβ3-integrin therapy on ovarian cancer tumors and the surrounding endothelial cells, before embarking on clinical therapeutic trials [18].

6. Conclusion

Recognition of the need for cytoreduction along with the evolution of surgical techniques and the establishment of chemotherapy regimens through multiple clinical trials allows a majority of ovarian cancer patients to achieve “disease-free” status after the initial treatment. One of the major disappointments with the current ovarian cancer treatments is failure to achieve a complete cure, even in optimally debulked or chemosensitive patients. The establishment of efficacious consolidation or maintenance therapies would be a powerful tool for improving the miserable outcomes of patients with advanced-stage disease.

The biological behavior of ovarian carcinoma is unique, differing from the classic and well-studied pattern of hematogenous metastasis found in most other cancers. Once ovarian cancer cells have detached as single cells or clusters from the primary ovarian tumor, they are carried by the physiological movement of peritoneal fluid and finally metastasize to the peritoneum and omentum, suggesting that the attachment of cancer cells onto the mesothelial cells covering the basement membrane is the initial key step in metastasis. Bevacizumab has already shown significant utility in ovarian cancer treatment not only in combination with current chemotherapy but also as a single agent, indicating that antiangiogenic therapy has considerable promise. Given that targeting integrins can affect not only the diverse functions of tumor cells, including adhesion, migration, invasion, protease expression, and colony formation in vitro, Cilengitide may have detrimental effects against ovarian cancer.
example, even if inhibition of the function of α5β1 integrin as a fibronectin receptor could be adequately achieved, the other integrins, such as αvβ3 or α3β1, would eventually compensate for its function. Therefore, a combination of different integrin receptor pathways is likely to be more effective in the clinical setting and should be explored for the future clinical application.

Collectively, although there remain many questions and challenges, integrin-targeted therapies continue to be a promising approach to improve the outcomes of women with ovarian cancer.

Conflicts of Interests

The authors state no conflict of interests and have received no payment in preparation of this paper.

Acknowledgments

The authors are grateful to Remina Emoto for her secretarial assistance. This work was supported in part by a Grant-in-Aid for scientific research from the Ministry of Education, Science, Sports and Culture of Japan (to K. Sawada).

References

[1] S. A. Cannistra, “Cancer of the ovary,” The New England Journal of Medicine, vol. 351, no. 24, pp. 2519–2565, 2004.
[2] H. Jin and J. Varner, “Integrins: roles in cancer development and as treatment targets,” British Journal of Cancer, vol. 90, no. 3, pp. 561–565, 2004.
[3] J. S. Desgrosellier and D. A. Cheresh, “Integrins in cancer: biological implications and therapeutic opportunities,” Nature Reviews Cancer, vol. 10, no. 1, pp. 9–22, 2010.
[4] W. Guo and F. G. Giancotti, “Integrin signalling during tumour progression,” Nature Reviews Molecular Cell Biology, vol. 5, no. 10, pp. 816–826, 2004.
[5] R. O. Hynes, “Integrins: bidirectional, allosteric signaling machines,” Cell, vol. 110, no. 6, pp. 673–687, 2002.
[6] Z. Wang, W. K. Chui, and P. C. Ho, “Integrin targeted drug and gene delivery,” Expert Opinion on Drug Delivery, vol. 7, no. 2, pp. 159–171, 2010.
[7] R. Stupp and C. Ruegg, “Integrin inhibitors reaching the clinic,” Journal of Clinical Oncology, vol. 25, no. 13, pp. 1637–1638, 2007.
[8] N. Makrila, A. Kollias, L. Manolopoulos, and K. Syrigos, “Cell adhesion molecules: role and clinical significance in cancer,” Cancer Investigation, vol. 27, no. 10, pp. 1023–1037, 2009.
[9] J. M. Nam, Y. Chung, H. C. Hsu, and C. C. Park, “β1 integrin targeting to enhance radiation therapy,” International Journal of Radiation Biology, vol. 85, no. 11, pp. 923–928, 2009.
[10] T. Sethi, R. C. Rintoul, S. M. Moore et al., “Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo,” Nature Medicine, vol. 5, no. 6, pp. 662–668, 1999.
[11] P. S. Hodkinson, T. Elliott, W. S. Wong et al., “ECM overrides DNA damage-induced cell cycle arrest and apoptosis in small-cell lung cancer cells through β1 integrin-dependent activation of PI3-kinase,” Cell Death and Differentiation, vol. 13, no. 10, pp. 1776–1788, 2006.
[12] A. Jemal, R. Siegel, J. Xu, and E. Ward, “Cancer statistics, 2010,” CA Cancer Journal for Clinicians, vol. 60, no. 5, pp. 277–300, 2010.
[13] R. C. Bast Jr., B. Hennessy, and G. B. Mills, “The biology of ovarian cancer: new opportunities for translation,” Nature Reviews Cancer, vol. 9, no. 6, pp. 415–428, 2009.
[14] S. S. Buys, E. Partridge, A. Black et al., “Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial,” JAMA, vol. 305, no. 22, pp. 2295–2303, 2011.
[15] R. E. Bristow, R. S. Tomacruz, D. K. Armstrong, E. L. Trimble, and F. J. Montz, “Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis,” Journal of Clinical Oncology, vol. 20, no. 5, pp. 1248–1259, 2002.
[16] K. K. Shin and D. S. Chi, “Maximal cytoreductive effort in epithelial ovarian cancer surgery,” Journal of Gynecologic Oncology, vol. 21, no. 2, pp. 75–80, 2010.
[17] E. Lengyel, “Ovarian cancer development and metastasis,” American Journal of Pathology, vol. 177, no. 3, pp. 1053–1064, 2010.
[18] A. A. Jazaeri and J. K. Slack-Davis, “The promise of antiangiogenic therapy for ovarian cancer,” Cancer Biology and Therapy, vol. 8, no. 23, pp. 2273–2274, 2009.
[19] S. Banerjee and M. Gore, “The future of targeted therapies in ovarian cancer,” Oncologist, vol. 14, no. 7, pp. 706–716, 2009.
[20] K. Sawada, A. K. Mitra, A. R. Radjabi et al., “Loss of E-cadherin promotes ovarian cancer metastasis via α5-integrin, which is a therapeutic target,” Cancer Research, vol. 68, no. 7, pp. 2329–2339, 2008.
[21] R. C. Casey, K. M. Burleson, K. M. Skubitz et al., “β1-integrins regulate the formation and adhesion of ovarian carcinoma multicellular spheroids,” American Journal of Pathology, vol. 159, no. 6, pp. 2071–2080, 2001.
[22] T. Strobel and S. A. Cannistra, “Beta1-integrins partly mediate binding of ovarian cancer cells to peritoneal mesothelium in vitro,” Gynecologic Oncology, vol. 73, no. 3, pp. 362–367, 1999.
[23] T. L. Moser, S. V. Pizzo, L. M. Bafetti, D. A. Fishman, and M. S. Stack, “Evidence for preferential adhesion of ovarian epithelial carcinoma cells to type I collagen mediated by the αβ1 integrin,” International Journal of Cancer, vol. 67, no. 5, pp. 695–701, 1996.
[24] J. K. Slack-Davis, K. A. Atkins, C. Harrer, E. Daniel Hershey, and M. Conaway, “Vascular cell adhesion molecule-1 is a regulator of ovarian cancer peritoneal metastasis,” Cancer Research, vol. 69, no. 4, pp. 1469–1476, 2009.
[25] N. Ahmed, F. Pansino, R. Clyde et al., “Overexpression of αvβ6 integrin in serous epithelial ovarian cancer regulates extracellular matrix degradation via the plasminogen activation cascade,” Carcinogenesis, vol. 23, no. 2, pp. 237–244, 2002.
[26] S. Kaur, H. A. Kenny, S. Jagadeeswaran et al., “β3-integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer,” American Journal of Pathology, vol. 175, no. 5, pp. 2184–2196, 2009.
[27] A. R. Reynolds, I. R. Hart, A. R. Watson et al., “Stimulation of tumor growth and angiogenesis by low concentrations of RGDF-mimetic integrin inhibitors,” Nature Medicine, vol. 15, no. 4, pp. 392–400, 2009.
[28] P. Khalili, A. Arakelian, G. Chen et al., “A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo,” Molecular Cancer Therapeutics, vol. 5, no. 9, pp. 2271–2280, 2006.
[29] C. N. Landen, T. J. Kim, Y. G. Lin et al., “Tumor-selective response to antibody-mediated targeting of αvβ3 integrin in ovarian cancer,” Neoplasia, vol. 10, no. 11, pp. 1259–1267, 2008.

[30] M. Bellone, E. Cocco, J. Varughese et al., “Expression of αV-integrins in uterine serous papillary carcinomas; implications for targeted therapy with intetumumab (CNTO 95), a fully human antagonist anti-αV-integrin antibody,” International Journal of Gynecological Cancer, vol. 21, no. 6, pp. 1084–1090, 2011.

[31] C. J. Avraamides, B. Garmy-Susini, and J. A. Varner, “Integrins in angiogenesis and lymphangiogenesis,” Nature Reviews Cancer, vol. 8, no. 8, pp. 604–617, 2008.

[32] K. M. Bell-McGuinn, C. M. Matthews, S. N. Ho et al., “A phase II, single-arm study of the anti-alpha5beta1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer,” Gynecologic Oncology, vol. 121, no. 2, pp. 273–279, 2011.

[33] F. Donato, G. C. Parry, Y. Shakde et al., “Pharmacology of the novel antiangiogenic peptide ATN-161 (Ac-PHSCN-NH 2): observation of a U-shaped dose-response curve in several prreclinical models of angiogenesis and tumor growth,” Clinical Cancer Research, vol. 14, no. 7, pp. 2137–2144, 2008.

[34] M. E. Cianfrocca, K. A. Kimmel, J. Gallo et al., “Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH 2), a beta integrin antagonist, in patients with solid tumours,” British Journal of Cancer, vol. 94, no. 11, pp. 1621–1626, 2006.

[35] P. C. Brooks, S. Stromblad, R. Klemke et al., “Anti-integrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin,” The Journal of Clinical Investigation, vol. 96, no. 4, pp. 1815–1822, 1995.

[36] J. A. Posey, M. B. Khazaeli, A. DelGrosso et al., “A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer,” Cancer Biother Radiopharm, vol. 16, no. 2, pp. 125–132, 2001.

[37] M. Trikha, Z. Zhou, J. A. Nemeth et al., “CNTO 95, a fully human monoclonal antibody that inhibits αv integrins, has antitumor and antiangiogenic activity in vivo,” International Journal of Cancer, vol. 110, no. 3, pp. 326–335, 2004.

[38] Q. Chen, C. D. Manning, H. Millar et al., “CNTO 95, a fully human anti αv integrin antibody, inhibits cell signaling, migration, invasion, and spontaneous metastasis of human breast cancer cells,” Clinical and Experimental Metastasis, vol. 25, no. 2, pp. 139–148, 2008.

[39] P. L. Martin, Q. Jiao, J. Cornacoff et al., “Absence of adverse effects in cynomolgus macaques treated with CNTO 95, a fully human anti-αv integrin monoclonal antibody, despite widespread tissue binding,” Clinical Cancer Research, vol. 11, no. 19, pp. 6959–6965, 2005.

[40] S. A. Mullamitha, N. C. Ton, G. J. Parker et al., “Phase I evaluation of a fully human anti-αv integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors,” Clinical Cancer Research, vol. 13, no. 7, pp. 2128–2135, 2007.

[41] L. B. Nabors, T. Mikkelsen, S. S. Rosenfeld et al., “Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma,” Journal of Clinical Oncology, vol. 25, no. 13, pp. 1651–1657, 2007.

[42] D. A. Reardon, K. L. Fink, T. Mikkelsen et al., “Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme,” Journal of Clinical Oncology, vol. 26, no. 34, pp. 5610–5617, 2008.